Belite Bio, Inc

NASDAQ: BLTE · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001889109Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 70DQ —GM —SS 51

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$77.6M

Employees

as of 2026-08-07

Market cap

$6.4B

as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$77.6M-$77.6M2025

Operating income-$84.2M-$84.2M2025

Total assets$780.6M$780.6M2025

Liabilities$10.1M$10.1M2025

Equity$770.5M$770.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Belite Bio, Inc’s financial profile?

Belite Bio, Inc earned -$77.6M in FY2025 net income.

Peers · Healthcare

Apogee Therapeutics, Inc.——Immunovant, Inc.——Vaxcyte, Inc.——Erasca, Inc.——Definium Therapeutics, Inc.——Dyne Therapeutics, Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOYu-Hsin Lin

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: BLTE

Employees41

IPO date2022-04-29

Latest filings

6-K2026-08-13 6-K2026-08-11 6-K2026-06-15 6-K2026-05-20 6-K2026-04-21 6-K2026-03-31 20-F2026-03-31 6-K2026-03-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.